Product number of Linuo Pharmaceutical Group

Inclusion in the National Catalog National New Drugs National Medical Insurance Catalog National Essential Drug Catalog Shandong Supplementary Catalog Kefeng 3 Category II New Drugs

1 Category III Drugs

Category IV 6 Category A and 12 Category B

10 Category B

Accounting for 56.4 and 11 of the total document numbers

Accounting for 28.2 and 10 of the total document numbers

Accounting for 25.6 of the total number, 92 Category A in Yongning

58 Category B

Accounting for 67.3, 94 of the total number

Accounting for 42,40 of the total number

Accounting for 40.9 of the total number, 3 Keyuan Class II new drugs

1 Class III new drug

16 Class IV new drugs

Six Category 2, a total of 6 Category II new drugs

2 Category III drugs

22 Category IV drugs

2 Category VI drugs, 104 Category A

Class B 68, 105, 50 authoritative certification quality assurance

2. Technical cooperation

The scientific research elite of Linuo Pharmaceutical Group, starting from humanized technology, track Advanced product technology at home and abroad, with 46 invention patents, 21 industry standards, and more than 3 new products every year are qualified to become star products in market segments, giving Linuo Pharmaceuticals a stronger brand in the high-end pharmaceutical market The right to speak.

Linuo Pharmaceutical Group has established strategic partnerships with world-renowned pharmaceutical institutions such as Sanofi, Novartis, and Atovis, and has also established strategic partnerships with East China University of Science and Technology, Shanghai Jiao Tong University, Shandong University, and Shandong Pharmaceutical Industry Research institutes and other universities and scientific research institutes have established extensive industry-university-research cooperation relationships, further enhancing technical support and R&D motivation.

East China University of Science and Technology

Shanghai Jiaotong University

Shandong Institute of Pharmaceutical Industry